|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0040808,
umls-concept:C0205179,
umls-concept:C0376495,
umls-concept:C0871261,
umls-concept:C0995188,
umls-concept:C1335499,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1708063,
umls-concept:C2911692
|
|
pubmed:issue |
3-4
|
|
pubmed:dateCreated |
2008-9-5
|
|
pubmed:abstractText |
We aimed to determine the response to cetuximab in advanced, chemotherapy-resistant, colorectal cancer following successful first-line therapy with the antibody.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0232
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2008 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
74
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
123-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18708729-Aged,
pubmed-meshheading:18708729-Aged, 80 and over,
pubmed-meshheading:18708729-Antibodies, Monoclonal,
pubmed-meshheading:18708729-Antineoplastic Agents,
pubmed-meshheading:18708729-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18708729-Clinical Trials, Phase I as Topic,
pubmed-meshheading:18708729-Clinical Trials, Phase II as Topic,
pubmed-meshheading:18708729-Colorectal Neoplasms,
pubmed-meshheading:18708729-Disease Progression,
pubmed-meshheading:18708729-Drug Resistance, Neoplasm,
pubmed-meshheading:18708729-Female,
pubmed-meshheading:18708729-Humans,
pubmed-meshheading:18708729-Male,
pubmed-meshheading:18708729-Middle Aged,
pubmed-meshheading:18708729-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18708729-Salvage Therapy,
pubmed-meshheading:18708729-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen.
|
|
pubmed:affiliation |
Department of Internal Medicine I, University of Ulm, Ulm, Germany.
|
|
pubmed:publicationType |
Journal Article
|
